Synergistic Effects in Apoptosis Induction by Taurolidine and TRAIL in HCT-15 Colon Carcinoma Cells

REFERENCES

• Fesik S W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876–885
   PubMed Web of Science ®Google Scholar
• Yagita H, Takeda K, Hayakawa Y, Smyth M J, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777–783
   PubMed Web of Science ®Google Scholar
• Bouralexis S, Findlay D M, Evdokiou A. Death to the bad guys: Targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10: 35–51
   PubMed Web of Science ®Google Scholar
• Rowinsky E K. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394–9407
   PubMed Web of Science ®Google Scholar
• Hylander B L, Pitoniak R, Penetrante R B, Gibbs J F, Oktay D, Cheng J, Repasky E A. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005; 3: 22
   PubMed Web of Science ®Google Scholar
• Naka T, Sugamura K, Hylander B L, Widmer M B, Rustum Y M, Repasky E A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800–5806
   PubMed Web of Science ®Google Scholar
• Cretney E, McQualter J L, Kayagaki N, Yagita H, Bernard C C, Grewal I S, Ashkenazi A, Smyth M J. TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol 2005; 83: 511–519
   Google Scholar
• Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005; 12: 228–237
   PubMed Web of Science ®Google Scholar
• Van Geelen C M, de Vries E G, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy. Drug Resist Updat 2004; 7: 345–358
   PubMed Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, De Forge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith C A, Strom S S, Kelley S, Fox J A, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383–385
   PubMed Web of Science ®Google Scholar
• Ganten T M, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas T L, Schader M B, Untergasser A, Stremmel W, Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2640–2646
   PubMed Web of Science ®Google Scholar
• Kim S H, Kim K, Kwagh J G, Dicker D T, Herlyn M, Rustgi A K, Chen Y, El-Deiry W S. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279: 40044–40052
   PubMed Web of Science ®Google Scholar
• Begue B, Wajant H, Bambou J C, Dubuquoy L, Siegmund D, Beaulieu J F, Canioni D, Berrebi D, Brousse N, Desreumaux P, Schmitz J, Lentze M J, Goulet O, Cerf-Bensussan N, Ruemmele F M. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006; 130: 1962–1974
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai R C, Fong S, Leung S, Lawrence D A, Marsters S A, Blackie C, Chang L, Mc Murtrey A E, Hebert A, De Forge L, Koumenis I L, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall R H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162
   PubMed Web of Science ®Google Scholar
• Jacobi C A, Menenakos C, Braumann C. Taurolidine—A new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005; 16: 917–921
   PubMedGoogle Scholar
• Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 2002; 22: 1959–1964
   Google Scholar
• Darnowski J W, Goulette F A, Cousens L P, Chatterjee D, Calabresi P. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 2004; 54: 249–258
   Google Scholar
• Braumann C, Henke W, Jacobi C A, Dubiel W. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 2004; 112: 225–230
   Google Scholar
• Rodak R, Kubota H, Ishihara H, Eugster H P, Konu D, Mohler H, Yonekawa Y, Frei K. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005; 102: 1055–1068
   PubMed Web of Science ®Google Scholar
• Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi C A. Prevention of disease progression in a patient with a gastric cancer recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 2006; 4: 34
   Google Scholar
• Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 2004; 24: 1143–1147
   Google Scholar
• Marini P, Schmid A, Jendrossek V, Faltin H, Daniel P T, Budach W, Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005; 5: 5
   PubMed Web of Science ®Google Scholar
• Tang X, Sun Y J, Half E, Kuo M T, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002; 62: 4903–4908
   PubMed Web of Science ®Google Scholar
• Cretney E, Shanker A, Yagita H, Smyth M J, Sayers T J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006; 84: 87–98
   PubMed Web of Science ®Google Scholar
• Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff H, Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 25: 7434–7439
   PubMed Web of Science ®Google Scholar
• Shrayer D P, Lukoff H, King T, Calabresi P. The effect of taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 2003; 14: 295–303
   Google Scholar
• Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, Dimanche-Boitrel M T. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003; 22: 1807–1816
   PubMedGoogle Scholar
• Langaas V, Shahzidi S, Johnsen J I, Smedsrod B, Sveinbjornsson B. Interferon-gamma modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 2001; 21: 3733–3738
   PubMed Web of Science ®Google Scholar
• Betjes M G, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19: 1546–1551
   PubMed Web of Science ®Google Scholar
• Willatts S M, Radford S, Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: A placebo-controlled, double-blind trial. Crit Care Med 1995; 23: 1033–1039
   PubMed Web of Science ®Google Scholar